Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)
China flag China · Delayed Price · Currency is CNY
7.50
+0.08 (1.08%)
Sep 18, 2026, 3:00 PM CST

SHA:600664 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
16,06915,90116,11915,40013,75512,741
Other Revenue
65.7363.2456.8356.2153.6361.06
16,13515,96416,17615,45713,80912,802
Revenue Growth
-0.14%-1.31%4.65%11.93%7.86%18.66%
Cost of Revenue
12,03111,85011,65511,44310,4469,826
Gross Profit
4,1044,1144,5214,0133,3632,976
Selling, General & Admin
3,0943,2203,3903,1432,5652,306
Research & Development
145.34145.01136.43106.02115.8197.73
Other Operating Expenses
146.03112.43108.29120.17122.65113.17
Operating Expenses
3,4343,5423,6713,3952,8052,528
Operating Income
669.57572.25849.71618.44557.91447.79
Interest Expense
-39.93-42.55-60.07-56.47-85.53-105.16
Interest & Investment Income
17.5124.3549.4751.5869.1916.5
Currency Exchange Gain (Loss)
-8.04-4.4-5.68-5.3731.99
Other Non Operating Income (Expenses)
-15.05-30.5266.61-22.74-19.44-5.07
EBT Excluding Unusual Items
624.06519.13900.04585.45525.13356.06
Gain (Loss) on Sale of Investments
-0.77-0.77---20-
Gain (Loss) on Sale of Assets
35.383.520.940.98161.38210.87
Asset Writedown
-2.59-2.59-59.84-15.13-32.52-2.33
Other Unusual Items
72.653.4533.8779.2567.1765.93
Pretax Income
728.67572.74875.01650.54701.15630.53
Income Tax Expense
184.7173.96184.4176.32188.94220.69
Earnings From Continuing Operations
543.97398.78690.61474.22512.21409.85
Minority Interest in Earnings
-31.76-37.18-61.76-78.95-47.06-38.76
Net Income
512.21361.6628.85395.26465.15371.08
Net Income to Common
512.21361.6628.85395.26465.15371.08
Net Income Growth
-6.04%-42.50%59.10%-15.02%25.35%-
Shares Outstanding (Basic)
2,5832,5832,5152,4702,4482,474
Shares Outstanding (Diluted)
2,5832,5832,5152,4702,5842,474
Shares Change
1.35%2.68%1.82%-4.40%4.46%-1.29%
EPS (Basic)
0.200.140.250.160.190.15
EPS (Diluted)
0.200.140.250.160.180.15
EPS Growth
-7.29%-44.00%56.25%-11.11%20.00%-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
360.27288.71691.69863.14532.45-239.13
Free Cash Flow Per Share
0.140.110.280.350.21-0.10
Gross Margin
25.44%25.77%27.95%25.96%24.35%23.24%
Operating Margin
4.15%3.58%5.25%4.00%4.04%3.50%
Profit Margin
3.17%2.27%3.89%2.56%3.37%2.90%
Free Cash Flow Margin
2.23%1.81%4.28%5.58%3.86%-1.87%
EBITDA
884.5789.311,090878.27821.32716.99
EBITDA Margin
5.48%4.94%6.74%5.68%5.95%5.60%
D&A For EBITDA
214.93217.06240.76259.83263.41269.2
EBIT
669.57572.25849.71618.44557.91447.79
EBIT Margin
4.15%3.58%5.25%4.00%4.04%3.50%
Effective Tax Rate
25.35%30.37%21.07%27.10%26.95%35.00%
Revenue as Reported
16,13515,96416,17615,45713,80912,802
Advertising Expenses
-1,5961,8061,5741,058340.89